Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 702-705

  Gregoor, Jochem G ^a,b   Mulder, Hans ^b,c   Cohen, Dan ^d   Van Megen, Harold J G M ^a   Egberts, Toine C G ^b,e   Heerdink, Eibert R ^b,e   Van Der Weide, Jan ^a  

^a Psychiatric Hospital Meerkanten   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Wilhelmina Ziekenhuis   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

antipsychotic; leptin; obesity; pharmacogenetic

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CLOZAPINE; LEPTIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CHILD; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEPTIN; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, LEPTIN; YOUNG ADULT;

EID: 78649341319     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181fa05a2     Document Type: Article

References (26)

1. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156: 1686-1696.
2. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol. 2001; 16:153-162.
3. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101:277-288.
4. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57.
5. Hugenholtz GW, Heerdink ER, Meijer WE, et al. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry. 2005;38:122-124.
6. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics. J Psychopharmacol. 2006;20:15-18.
7. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359:2086-2087.
8. Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005;15: 195-200.
9. Gregoor JG, van der Weide J, Mulder H, et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol. 2009;29:21-25.
10. Mulder H, Franke B, van der-Beek van der AA, Arends J, et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J. 2007;7:318-324.
11. Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol. 2009;29:16-20.
12. Zhang XY, Tan YL, Zhou DF, et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol. 2007;27:246-251.
13. De Luca V, Mueller DJ, de Bartolomeis A, et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol. 2007;10:697-704.
14. Kang SG, Lee HJ, Park YM, et al. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:160-163.
15. Dryden S, Brown M, King P, et al. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res. 1999;31:363-366.
16. Yamada J, Sugimoto Y, Ujikawa M. The serotonin precursor 5-hydroxytryptophan elevates serum leptin levels in mice. Eur J Pharmacol. 1999;383:49-51.
17. Yamada J, Sugimoto Y, Ujikawa M. Involvement of leptin in hypophagia induced by the serotonin precursor 5-hydroxytryptophan (5-HTP) in mice. Biol Pharm Bull. 2006;29:557-559.
18. Calapai G, Corica F, Corsonello A, et al. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J Clin Invest. 1999;104:975-982.
19. Charnay Y, Cusin I, Vallet PG, et al. Intracerebroventricular infusion of leptin decreases serotonin transporter binding sites in the frontal cortex of the rat. Neurosci Lett. 2000;283:89-92.
20. Hay-Schmidt A, Helboe L, Larsen PJ. Leptin receptor immunoreactivity is present in ascending serotonergic and catecholaminergic neurons of the rat. Neuroendocrinology. 2001;73:215-226.
21. Yevtushenko OO, Cooper SJ, O'Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry. 2008;192:424-428.
22. Preventing and managing the global epidemic. Report on a WHO consultation on Obesity. Geneva: World Health Organisation; 1998: 3-5 June 1997.
23. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64:701-723.
24. Yevtushenko O, Cooper S, O'Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry. 2008;192:424-428.
25. Yamada J, Ujikawa M, Sugimoto Y. Serum leptin levels after central and systemic injection of a serotonin precursor, 5-hydroxytryptophan, in mice. Eur J Pharmacol. 2000;406:159-162.
26. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin levels in patients with premature ejaculation before and after citalopram treatment. BJU Int. 2003;91:252-254.